selected scholarly activity
-
conferences
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 double-blind, placebo-controlled trial. Movement Disorders. S107-S107. 2018
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from a Phase 3 double-blind, placebo-controlled trial. Movement Disorders. S165-S165. 2018
- A pilot study to examine the single dose pharmacokinetic properties of two formulations of Apomorphine Sublingual Film (APL-130277) 15 mg in health volunteers. European Journal of Neurology. 397-397. 2017
- Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease (PD) from OFF to fully ON: preliminary results from a phase iii study. Movement Disorders. 2017
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: results from the Phase 3 study dose-titration phase. Movement Disorders. 2017
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: preliminary results from a Phase III Study. Movement Disorders. 2017
- Study design of an efficacy and safety phase 3, randomized, double-blind, placebo-controlled trial of APL-130277 in the treatment of OFF episodes (CTH-300). Movement Disorders. 2017
- Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease(PD) from OFF to fully ON. Journal of The American Geriatrics Society. S178-S178. 2017
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Preliminary results from the Phase 3 study dose-titration phase. Journal of The American Geriatrics Society. S178-S178. 2017
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: preliminary results from the Phase 3 study dose titration phase. Journal of The American Geriatrics Society. S177-S178. 2017
- Efficacy of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 study dose-titration phase. Movement Disorders. S35-S36. 2017
- Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease: Results from the Phase 3 study dose titration phase. Movement Disorders. S39-S39. 2017
- Study design of an efficacy and safety phase 3, randomized, double-blind, placebo-controlled trial of APL-130277 in the treatment of OFF episodes (CTH-300). Movement Disorders. S36-S37. 2017
- APL-130277 is a sublingual film being studied in phase 3 trials to rapidly turn patients ON from OFF episodes by delivering apomorphine via the oral mucosa. Movement Disorders. S274-S274. 2016
- Disease severity is not predictive of the dose required for apomorphine sublingual film (APL-130277) to convert a patient with Parkinson's disease from OFF to fully ON. Movement Disorders. S271-S271. 2016
- Minimum MDS-UPDRS part III change needed to convert a Parkinson's disease patient from the OFF to full ON state with apomorphine sublingual film (APL-130277). Movement Disorders. S275-S275. 2016
- Oral apomorphine film (APL-130277) produces no buccal mucosal irritation: Results of a toxicological study. Movement Disorders. S273-S273. 2016
- Oral sublingual apomorphine film (APL-130277) produces no buccal mucosal irritation: results of a toxicological study. European Journal of Neurology. 658-658. 2016
- Pharmacokinetic-pharmacodynamic effects of apomorphine sublingual film (APL-130277) for the rapid management of OFF episodes in patients with Parkinson's disease. Movement Disorders. S275-S275. 2016
- Treatment of OFF episodes in Parkinson's disease: An evaluation of patient and caregiver insights. Movement Disorders. S271-S271. 2016
- Treatment of OFF episodes in Parkinson's disease: An evaluation of physician practices. Movement Disorders. S271-S272. 2016
- Treatment of OFF episodes in Parkinson's disease: an evaluation of patient and caregiver insights. European Journal of Neurology. 657-657. 2016
- Treatment of OFF episodes in Parkinson's disease: an evaluation of physician practices. European Journal of Neurology. 658-658. 2016
- Efficacy of Sublingual Apomorphine (APL-130277) for the Treatment of "Off" Episodes in Patients with Parkinson's Disease. Annals of Neurology. S44-S44. 2015
- Pharmacokinetic-Pharmacodynamic Effects of Sublingual Apomorphine (APL-130277) for the Acute Management of OFF Episodes in Parkinson's Disease Patients. Annals of Neurology. S47-S48. 2015
- Pharmacokinetics, Safety and Tolerability of Sub-Lingually Administered Apomorphine (APL-130277) Compared to Subcutaneous Apomorphine in Healthy Volunteers. Annals of Neurology. S44-S44. 2015
- Safety of Sublingual Apomorphine (APL-130277) for the Treatment of OFF Episodes in Patients with Parkinson's Disease. Annals of Neurology. S47-S47. 2015
- Pharmacokinetic-Pharmacodynamic effects of sublingual apomorphine (APL-130277) for acute rescue of OFF episodes in Parkinson's disease patients. Neurology. E48-E48. 2015
- Efficacy of sublingual apomorphine (APL-130277) for the treatment of "Off" episodes in patients with Parkinson's disease. European Journal of Neurology. 249-249. 2015
- Efficacy of sublingual apomorphine (APL-130277) for the treatment of "off" episodes in patients with Parkinson's disease. Movement Disorders. S90-S90. 2015
- Pharmacokinetics, safety and tolerability of high-dose sub-lingually administered APL-130277 in healthy volunteers. Movement Disorders. S65-S66. 2015
- Pharmacokinetics, safety and tolerability of sub-lingually administered APL-130277 compared to subcutaneous apomorphine in healthy volunteers. Movement Disorders. S64-S65. 2015
- Safety of sublingual APL-130277 for the treatment of OFF episodes in patients with Parkinson's disease. Movement Disorders. S94-S95. 2015
- Safety of sublingual apomorphine (APL-130277) for the treatment of OFF episodes in patients with Parkinson's disease. European Journal of Neurology. 250-250. 2015
- The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: A double-blind, placebo-controlled trial in patients with ESRD. American Journal of Kidney Diseases. S48-S53. 2001
- ONCOSTATIN-M REGULATES CYTOKINE RELEASE FROM FIBROBLASTS BUT NOT PERIPHERAL-BLOOD MONOCYTES OR NEUTROPHILS. The FASEB Journal. A222-A222. 1994
- EFFECT OF RHEUMATOID-ARTHRITIS SERUM (RA-SE) AND SYNOVIAL-FLUID (-SF) ON IL-8 AND GM-CSF PRODUCTION BY HUMAN SYNOVIOCYTES (SYN). The FASEB Journal. A1898-A1898. 1992
- INHIBITION OF MURINE INTESTINAL INFLAMMATION BY ANTI-SUBSTANCE-P ANTIBODY. The FASEB Journal. A1993-A1993. 1992
- REGULATION OF TIMP EXPRESSION IN SYNOVIAL FIBROBLASTS BY PGE2 AND CYTOKINES. The FASEB Journal. A941-A941. 1992
- THE APPARENT LACK OF CELL-CYCLE DEPENDENCY FOR SUBSTANCE-P BINDING TO MURINE LYMPHOCYTES. ONTOGENETIC AND PHYLOGENETIC MECHANISMS OF NEUROIMMUNOMODULATION. 226-228. 1992
-
journal articles
- Buccal Mucosal Irritation Studies of Sublingual Apomorphine Film (APL-130277) in Syrian Golden Hamsters. Therapeutic delivery. 7:611-618. 2016
- Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease. Movement Disorders. 31:1366-1372. 2016
- Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: A one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness. Clinical Therapeutics. 23:1492-1507. 2001
- The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with esrd.. American Journal of Kidney Diseases. 37:S48-S53. 2001
- Nippostrongylus brasiliensisinfection evokes neuronal abnormalities and alterations in neurally regulated electrolyte transport in rat jejunum. Parasitology. 113:173-182. 1996
- Prostaglandin E2 enhances interleukin 8 (IL-8) and IL-6 but inhibits GMCSF production by IL-1 stimulated human synovial fibroblasts in vitro.. Journal of Rheumatology. 23:862-868. 1996
- Oncostatin M inhibits IL-1-induced expression of IL-8 and granulocyte-macrophage colony-stimulating factor by synovial and lung fibroblasts.. Journal of Immunology. 156:343-349. 1996
- Neuroimmunomodulation: classical and non-classical cellular activation. Advances in Neuroimmunology. 5:311-319. 1995
- Inhibitory effect of diazepam on human natural killer activity in vitro.. Cytobios. 77:131-136. 1994
- Interaction between oncostatin M, interleukin 1 and prostaglandin E2 in induction of IL-6 expression in human fibroblasts. Cytokine. 6:40-47. 1994
- Substance-P-Mediated Intestinal Inflammation: Inhibitory Effects of CP 96,345 and SMS 201-995. NeuroImmunoModulation. 1:350-356. 1994
- Immunomodulatory properties of diazepam-binding inhibitor: Effect on human interleukin-6 secretion, lymphocyte proliferation and natural killer cell activity in vitro. Neuropeptides. 25:207-211. 1993
- Inhibition of murine intestinal inflammation by anti-substance P antibody.. Regional immunology. 5:120-126. 1993
- Synoviocyte derived granulocyte macrophage colony stimulating factor mediates the survival of human lymphocytes.. Journal of Rheumatology. 19:1065-1069. 1992
- Increased levels of substance P in the myenteric plexus of Trichinella-infected rats. Gastroenterology. 102:1913-1919. 1992
- The Apparent Lack of Cell Cycle Dependency for Substance P Binding to Murine Lymphocytes. Annals of the New York Academy of Sciences. 650:226-228. 1992
- Are lymphocytes a target for substance P modulation in arthritis?. Seminars in Arthritis and Rheumatism. 21:252-258. 1992
- Immunomodulatory activities of the somatostatin analogue BIM 23014c: effects on murine lymphocyte proliferation and natural killer activity. Regulatory Peptides. 32:129-139. 1991
- β-Endorphin in pituitary intraglandular colloid of intermediate lobe origin. Regulatory Peptides. 12:25-29. 1991
- Intraglandular colloid induced nuclear proliferation of murine thymic cells as determined by flow cytometry.. Endocrine Regulations. 24:385-394. 1990
- Neuromodulation of mucosal immunity.. Regional immunology. 2:414-419. 1989